Ultragenyx Pharmaceutical (RARE)
(Delayed Data from NSDQ)
$44.86 USD
-0.20 (-0.44%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $44.83 -0.03 (-0.07%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Price, Consensus and EPS Surprise
RARE 44.86 -0.20(-0.44%)
Will RARE be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for RARE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RARE
Ultragenyx (RARE) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Ionis (IONS) Up 6% on Detailed Data From Angelman Drug Study
RARE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans
Ultragenyx (RARE) to Seek Accelerated Nod for Rare Disease Drug
Ultragenyx (RARE) Moves 7.8% Higher: Will This Strength Last?
Other News for RARE
Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update
Leerink upgrades Ionis to outperform, cites Angelman drug
Ultragenyx to present GTX-102 Angelman syndrome program update
Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium
Ultragenyx Pharmaceutical (RARE) Gets a Buy from Evercore ISI